CSF protein patterns and CXCL7 were linked to ALS progression and survival
Original source
Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human
Related topics
A study found that cerebrospinal fluid (CSF) protein profiles distinguished people with amyotrophic lateral sclerosis (ALS) from healthy controls and separated patient groups by survival. CXCL7 showed potential as a complementary diagnostic and prognostic biomarker to neurofilament light chain (NfL), with findings supported by immunoassays in an independent cohort. Lipid profiles were less useful for distinguishing the groups.
Why this matters
These findings could help researchers develop more precise ways to classify ALS and estimate disease progression. The results do not yet change treatment or establish that measuring CXCL7 improves decisions for individual patients.
Limitations and context
This was a biomarker study using CSF profiling, machine-learning analyses, an independent validation cohort, and post-mortem spinal-cord tissue. The source does not provide cohort sizes or detail how the tests would perform in routine clinical care. The findings show associations with diagnosis and survival, not a treatment benefit or proof that CXCL7 can guide care.